Market Access News | pharmaphorum

News

digital health technologies for diabetes management

Digital diabetes tools ‘of little benefit and raise costs’

The recently formed Peterson Health Technology Institute (PHTI) has published its first assessment of the cost-effectiveness of digital health technologies (DHTs), focusin

News

Orchard’s MLD gene therapy becomes costliest US medicine

Orchard Therapeutics has revealed its US pricing plans for Lenmeldy, its gene therapy for metachromatic leukodystrophy (MLD), placing a $4.25 million price tag on the one-

News

Iclusig gets FDA nod as frontline therapy for rare leukaemia

Takeda’s Iclusig has become the first targeted therapy approved by the FDA for use alongside chemotherapy as a first-line therapy for a rare form of acute lymphoblastic le

News

EU pharma legislation reforms inch closer to fruition

A key hurdle in front of the EU reforms to pharma legislation has fallen, after the European Parliament’s Environment, Public Health and Food Safety (ENVI) committee appro

News

Vicore’s lung disease digital therapy gets breakthrough tag

Swedish pharma company Vicore has won breakthrough status from the FDA for Almee, a cognitive behavioural therapy (CBT) app used to support people with pulmonary fibrosis

News

Bayer cues up filings for rival to Astellas’ menopause drug

Armed with new phase 3 data, Bayer has started preparing filings for elinzanetant as a treatment for vasomotor symptoms (VMS) associated with menopause, setting up a chall

Digital diabetes tools ‘of little benefit and raise costs’

Orchard’s MLD gene therapy becomes costliest US medicine

Iclusig gets FDA nod as frontline therapy for rare leukaemia

EU pharma legislation reforms inch closer to fruition

Vicore’s lung disease digital therapy gets breakthrough tag

Bayer cues up filings for rival to Astellas’ menopause drug

PTC pulls file for Duchenne therapy on FDA feedback

How to meet your physicians where they are online

News

Editor's Picks